RT Journal Article
SR Electronic
T1 Community factors and excess mortality in the COVID-19 pandemic in England, Italy and Sweden
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.26.22274332
DO 10.1101/2022.04.26.22274332
A1 Parkes, Brandon
A1 Stafoggia, Massimo
A1 Fecht, Daniela
A1 Davies, Bethan
A1 Bonander, Carl
A1 de’ Donato, Francesca
A1 Michelozzi, Paula
A1 Piel, Frédéric B.
A1 Strömberg, Ulf
A1 Blangiardo, Marta
YR 2022
UL http://medrxiv.org/content/early/2022/04/27/2022.04.26.22274332.abstract
AB Analyses of COVID-19 suggest specific risk factors make communities more or less vulnerable to pandemic related deaths within countries. What is unclear is whether the characteristics affecting vulnerability of small communities within countries produce similar patterns of excess mortality across countries with different demographics and public health responses to the COVID-19 pandemic. We applied a two-stage Bayesian spatial model to quantify inequalities in excess mortality in people aged 40 years and older at the community level in England, Italy and Sweden during the first year of the pandemic (March 2020– February 2021). We used community characteristics measuring deprivation, air pollution, living conditions, population density and movement of people as model covariates to quantify their associations with excess mortality. We found that just under half of communities in England (48.1%) and Italy (45.8%) had an excess mortality of over 300 per 100,000 males over the age of 40, while for Sweden that covered 23.1% of the community-level areas. We showed that deprivation is a strong predictor of excess mortality across the three countries, and communities with high levels of overcrowding were associated with higher excess mortality in England and Sweden. These results highlight some international similarities in factors affecting mortality that will help policy makers target public health measures to increase the resilience of communities to the mortality impacts of this and future pandemics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work of the UK Small Area Health Statistics Unit is overseen by UK Health Security Agency (UK HSA) and supported by the UK Medical Research Council, Grant number: MR/L01341X/1), and the National Institute for Health Research (NIHR) through its Health Protection Units (HPRUs) at Imperial College London in Environmental Exposures and Health and in Chemical and Radiation Threats and Hazards, and through Health Data Research UK (HDR UK). M.B., B.P., F.P., B.D. & D.F. acknowledge infrastructure support for the Department of Epidemiology and Biostatistics provided by the NIHR Imperial BRC. The work was partially supported by the MRC Centre for Environment and Health, which is funded by the Medical Research Council (MR/S019669/1, 2019-2024). C.B. and U.S. acknowledge funding from the Swedish Research Council for Health, Working-Life and Welfare under Grant 2020-00962 and the Swedish Cancer Society under Grant 20 0719.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:London - South East Research Ethics Committee - reference 17/LO/0846 gave ethical approval for this work Health Research Authority - Confidentiality Advisory Group - HRA CAG reference: 20/CAG/0028 gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors